leadf
logo-loader
viewQ BioMed Inc.

Q BioMed receives recognition for its Strontium89 bone cancer pain relief advertisement

The company's marketing campaign for its FDA-approved treatment for bone cancer pain has been selected for inclusion in the prestigious Ads of the World's Best Creative Campaigns

Q BioMed
Q BioMed says its Strontium89 "Unfinished Business" ad expresses the "pain-free possibilities" for patients

Q BioMed Inc (OTCQB:QBIO) on Friday announced that its marketing campaign for Strontium89, a US Food and Drug Administration-approved treatment for the pain associated with bone cancer, has been selected for inclusion in the Ads of the World, a curated archive of the world's best creative campaigns.

The company noted that this recognition supports its efforts in making Strontium89 available to patients who need relief from metastatic bone cancer pain.

Q BioMed CEO Denis Corin said in a statement: "Q BioMed is committed to making Strontium89, an effective treatment for pain resulting from bone metastases, widely available again. Our Unfinished Business ad campaign echoes our mission of enabling patients to once again enjoy the simple things in life with their loved ones, while experiencing relatively long-term pain relief."

READ: Q BioMed has a winner in cancer bone pain drug Strontium89 and a deep pipeline of biomedical assets

He added: "We've been very pleased with our highly productive partnership with Makers Mage. Their vision and execution is a key part of our team's tireless efforts to get Strontium89 to those who need it most."

Strontium89's "Unfinished Business" ad, created by Philadelphia-based agency Makers Mage, expresses what the company calls the beautiful moments of daily life that can be realized when pain relief is achieved. Captions include "More moments with less pain" and "Expand your patients' pain-free possibilities." 

Strontium89, the radiotherapy with nearly 30 years of proven pain relief results for bone metastases, is available in the US. In the Strontium89 pivotal trial, as many as 79% of patients had pain relief with Strontium89, and twice as many patients treated with Strontium89 had no pain for three months compared with placebo, with new pain sites less frequent in patients treated with Strontium89.

Ads of the World is part of the Clio Network, which recognizes innovation and creative excellence in advertising, design, and communication as judged by an international panel of advertising professionals.

Q BioMed is a New York City-based company with a pipeline of drugs and therapies to treat metastatic cancer bone pain, pediatric non-verbal autism, liver cancer and glaucoma.

Contact Sean at [email protected]

Quick facts: Q BioMed Inc.

Price: 1.07 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $25.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Q BioMed gets US patent for its Uttrocide-B molecule as a potential liver...

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive it has received a US patent for its Uttrocide-B molecule as a potential liver cancer treatment. Corin says the company now has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology,...

1 week, 5 days ago

2 min read